K.J. Harrison & Partners Inc Abb Vie Inc. Transaction History

K.J. Harrison & Partners Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$137.62 - $174.96 $68,121 - $86,605	-495 Reduced 25.58%	1,440 $221,000
Q4 2021 Jan 26, 2022	SELL	$107.43 - $135.93 $505,243 - $639,278	-4,703 Reduced 70.85%	1,935 $262,000
Q3 2021 Nov 05, 2021	BUY	$106.4 - $120.78 $425,600 - $483,120	4,000 Added 151.63%	6,638 $720,000
Q2 2021 Aug 04, 2021	BUY	$105.21 - $117.21 $2,945 - $3,281	28 Added 1.07%	2,638 $297,000
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $7,161 - $7,883	-70 Reduced 2.61%	2,610 $282,000
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $66,806 - $90,196	-830 Reduced 23.65%	2,680 $287,000
Q3 2020 Nov 09, 2020	BUY	$85.91 - $100.83 $124,569 - $146,203	1,450 Added 70.39%	3,510 $308,000
Q2 2020 Aug 03, 2020	BUY	$73.37 - $98.18 $151,142 - $202,250	2,060 New	2,060 $202,000
Q4 2018 Jan 24, 2019	SELL	$77.85 - $96.01 $374,069 - $461,328	-4,805 Closed	0 $0
Q3 2018 Oct 26, 2018	BUY	$88.91 - $98.84 $79,129 - $87,967	890 Added 22.73%	4,805 $454,000
Q1 2018 Apr 30, 2018	BUY	$92.01 - $123.21 $360,219 - $482,367	3,915 New	3,915 $371,000

3,891

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $325B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of K.J. Harrison & Partners Inc, based on Form 13F filings with the SEC.

Stay updated on K.J. Harrison & Partners Inc with notifications on news.